MARKET

BLRX

BLRX

BioLine RX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.160
-0.090
-2.77%
After Hours: 3.110 -0.05 -1.58% 19:59 05/11 EDT
OPEN
2.940
PREV CLOSE
3.250
HIGH
3.330
LOW
2.810
VOLUME
3.67M
TURNOVER
--
52 WEEK HIGH
6.34
52 WEEK LOW
1.400
MARKET CAP
142.72M
P/E (TTM)
-1.7296
1D
5D
1M
3M
1Y
5Y
64 Biggest Movers From Yesterday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 82.6% to settle at $6.39 on Monday.
Benzinga · 19h ago
40 Stocks Moving In Monday's Mid-Day Session
Gainers Protagenic Therapeutics, Inc. (NASDAQ: PTIX) shares jumped 64.2% to $3.4962 on above-average news.
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 1d ago
20 Stocks Moving in Monday's Pre-Market Session
Gainers Alfi, Inc. (NASDAQ: ALF) shares rose 30.3% to $4.82 in pre-market trading. The company recently appointed Ron Spears as Chief Revenue Officer.
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Benzinga · 6d ago
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 64.9% to $7.75 after the company reported an order for 200,000 sugarBEAT sensors.
Benzinga · 6d ago
Parkinson's Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
May 05, 2021 (Financial News Media via COMTEX) -- Palm Beach, FL - May 5, 2021 – Parkinson’s disease (PD) is a neurodegenerative disorder that affects...
Financial News Media · 6d ago
Thinking about buying stock in Chiasma, Athenex, iBio, BioLineRx, or Endra Life Sciences?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHMA, ATNX, IBIO, BLRX, and NDRA.
PR Newswire - PRF · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLRX. Analyze the recent business situations of BioLine RX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLRX stock price target is 13.00 with a high estimate of 19.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 2.08M
% Owned: 4.63%
Shares Outstanding: 45.17M
TypeInstitutionsShares
Increased
3
35.70K
New
8
579.57K
Decreased
5
37.50K
Sold Out
5
2.81M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Chief Scientific Officer
Merril Gersten
Vice President
Ella Sorani
Vice President
Moshe Phillip
Vice President
Abi Vainstein-Haras
Vice President - Business Development
David Malek
Vice President - Business Development
Hillit Mannor Shachar
Director
Michael Anghel
Director
Barbara-Jean Bormann
Director
Raphael Hofstein
General Manager
Leah Klapper
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Director
Jacob Friedman
No Data
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers kinds of BioLine RX Ltd stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.